Increased risk of sudden sensorineural hearing loss in patients with hepatitis virus infection

Hsin-Chien Chen¹, Chi-Hsiang Chung²,³, Chih-Hung Wang¹, Jung-Chun Lin⁴, Wei-Kuo Chang⁴, Fu-Huang Lin³, Chang-Huei Tsao², Yung-Fu Wu², Wu-Chien Chien²,³*

¹ Department of Otolaryngology-Head and Neck surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ² Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ³ School of Public Health, National Defense Medical Center, Taipei, Taiwan, ⁴ Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

* doc30459@gmail.com

Abstract

The etiology of sudden sensorineural hearing loss (SSNHL) remains unclear. Possible causes of SSNHL include vascular diseases, viral infection, and autoimmune disorders. Therefore, we investigated whether hepatitis virus infection is correlated with the risk of SSNHL. Using data from the Taiwan Longitudinal Health Insurance Database, we conducted a retrospective matched-cohort study to compare patients diagnosed with hepatitis B or C virus (HBV/HCV) infections from January 1, 2000, to December 31, 2010, (N = 170,942) with frequency-matched controls (N = 512,826) at a ratio of 1:3 by sex, age, and index year. We followed each patient until the end of 2010 and evaluated the incidence of SSNHL. At the end of the follow-up period, 647 (0.38%, 647/170,942) patients developed SSNHL in the HBV/HCV group compared with 978 (0.19%, 978/512,826) in the control groups, with a statistical significance of \( P < 0.001 \) (using the log-rank test). The incidence rate ratio of SSNHL was 5.743-fold higher in the HBV/HCV group than in the control group (283.17 vs. 49.31 per 100,000 person-years, \( P < 0.001 \)). The risk of SSNHL increased with HBV/HCV infection, and an adjusted hazard ratio of 5.103 (95% CI, 4.585–5.678) was determined using Cox proportional hazards regression. This study contributes to the awareness of the increased risk of SSNHL in HBV/HCV-infected populations. Our findings suggest that an underlying viral infection contributes to the development of SSNHL.

Introduction

Sudden sensorineural hearing loss (SSNHL) is often an unexpected and traumatic experience for patients. SSNHL is defined as a sudden loss of more than 30 dB of hearing acuity in three contiguous frequencies within 72 h [1]. SSNHL is usually classified as idiopathic because the causative factor is not identified in most cases [2]. The potential causes of SSNHL include vascular disorders, viral infection, autoimmune disorders, neurological disorders, neoplasms, and ototoxic drugs [3].
Several studies have discussed the presence of viral infection in patients with SSNHL [4–6], and the types of viruses implicated in such cases include mumps, cytomegalovirus, measles, rubella, varicella zoster virus, herpes simplex virus, enteroviruses, and human immunodeficiency virus [5–7]. Hepatitis virus infection has been correlated with SSNHL in only a small number of case reports [8–11]. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections have emerged as a global health problem, and as many as 350 million and 123 million individuals have been infected with HBV and HCV, respectively, worldwide [12, 13]. In highly endemic areas such as Taiwan, the prevalence of chronic HBV infection is estimated to be between 15% and 20% [14, 15], whereas the prevalence of HCV is estimated at 4%–10% in the general population [16, 17]. Chronic HBV or HCV infections have been proven to increase the risk of hepatocellular carcinoma [18]. We are interested in investigating whether HBV or HCV infections have an impact on the incidence of SSNHL.

To assess the association between HBV or HCV infection and the subsequent development of SSNHL, we conducted a nationwide population-based cohort study by analyzing data from a nationwide medical database, the National Health Insurance Research Database.

Materials and methods

Data sources

In this study, we used data from the National Health Insurance Research Database (NHIRD) to investigate the association between hepatitis virus infections, including HBV and HCV infection, and SSNHL over a 10-year period (2000–2010), from the outpatient and hospitalization Longitudinal Health Insurance Database in Taiwan.

Study design and sampled participants

**Study design.** This study was a retrospective matched-cohort design.

**Sample.** Patients with HBV or HCV infections were selected from 1 January 2000 to 31 December 2010, according to the International Classification of Diseases, Version 9, Clinical Modification (ICD-9-CM) codes 070.20, 070.22, 070.30, 070.32, and V02.61 for HBV and 070.41, 070.44, 070.51, 070.54, 070.70, 070.71, and V02.62 for HCV. Patients diagnosed with SSNHL (ICD-9-CM code: 388.2) before 2000 or before the first visit for viral hepatitis were excluded. In addition, all patients aged <20 years were also excluded. A total of 683,768 participants were enrolled in this study; among these, 170,942 had HBV or HCV infection and 512,826 were controls without HBV or HCV infection who were matched by age, sex, and index year (Fig 1).

Covariates

The covariates included sex and age group (20–29, 30–39, 40–49, 50–59, 60–69, ≥70 years).

Comorbidity

Baseline comorbidities included diabetes mellitus (DM; ICD-9-CM code: 250); hypertension (ICD-9-CM codes: 401–405); depression (ICD-9-CM codes: 296.2, 296.3, 296.82, 300.4, and 311); stroke (ICD-9-CM codes: 430–438); chronic kidney disease (CKD; ICD-9-CM code: 585); osteoporosis (ICD-9-CM codes: 733.00–733.09); nephritis, nephrotic syndrome, and nephrosis (ICD-9-CM codes: 580–589); hyperlipidemia (ICD-9-CM code: 272); and systemic lupus erythematosus (SLE; ICD-9-CM code: 710.0).
Data analysis

All statistical analyses were performed using IBM SPSS for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA). $\chi^2$ and t tests were used to evaluate the distributions of categorical and continuous variables, respectively. Multivariate Cox proportional hazards regression analysis was used to determine the risk of SSNHL, and the results are presented as hazard ratio (HR) with 95% confidence interval (CI). The difference in the risk of SSNHL between the study (with HBV/HCV) and control (without HBV/HCV) groups was estimated using the Kaplan–Meier method with the log-rank test. A two-tailed $P$ value of $<0.05$ was considered to indicate statistical significance.

Ethics statement

This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The NHIRD encrypts personal patient information to maintain privacy and provides researchers with anonymous identification numbers associated with relevant claim information. Patient consent is not required for accessing the NHIRD. The Institutional Review Board of Tri-Service General Hospital approved this study (TSGHIRB No. 2-104-05-126). The committee waived the need for written informed consent.

Results

Characteristics of the prevalence of SSNHL, covariates, and comorbidities at the end of follow-up for patients with HBV/HCV infection compared with those without HBV/HCV infection

According to the assessed data from January 1, 2000, to December 31, 2010, 170,942 patients with HBV/HCV infection fulfilled the eligibility criteria and 512,826 matched individuals were selected as controls (Fig 1). In our matched-cohort study, no significant differences were
observed between the HBV/HCV and control groups in sex and age distribution at baseline. At the end of follow-up (Table 1), 647 (0.38%, 647/170,942) patients developed SSNHL in the HBV/HCV group compared with 978 (0.19%, 978/512,826) in the control group; this difference was statistically significant (P < 0.001). Additionally, in the HBV/HCV group, a higher rate of the participants was observed among those in the 20–59-year age group (58.39% vs. 51.37%) and those with some comorbidities (depression, 1.09% vs. 0.81%; SLE, 0.18% vs. 0.13%) compared with the control group.

Kaplan–Meier model for cumulative risk of SSNHL in HBV/HCV infection

The cumulative incidence curve for SSNHL in the total HBV/HCV infection cohort was significantly higher than that for the comparison cohort, after adjustment for age, sex, and comorbidities (Fig 2, log-rank test; P < 0.001). In the patients with HBV/HCV infections, the risk of SSNHL increased progressively with the duration of follow-up, rather than with being limited to the immediate days after a diagnosis of HBV/HCV infection. In the subgroups of HBV and HCV infection, the same trend was independently revealed (Fig 2).

HRs and incidence of SSNHL stratified by sex, age group, and comorbidities, by using Cox regression for patients with HBV/HCV infection compared with those without HBV/HCV infection

Cox proportional hazards regression analysis revealed an increased risk of SSNHL, with an adjusted HR of 5.103 (95% CI, 4.585–5.678), in patients with HBV/HCV infection, after adjustment for sex, age, and comorbidities (Table 2). Adjusted HRs of 4.825 (95% CI, 4.216–5.521) and 5.582 (95% CI, 4.686–6.651) for developing SSNHL were observed in male and female patients with HBV/HCV infection, respectively, compared with the control group (P < 0.001). Among all age groups, a higher adjusted HR for SSNHL was observed in the HBV/HCV group than in the control group. Regardless of the presence of the comorbidities of DM; hypertension; depression; stroke; CKD; osteoporosis; nephritis, nephrotic syndrome, and nephrosis; and hyperlipidemia, a higher adjusted HR (ranging from 2.356 to 15.114) was observed in patients with HBV/HCV infection than in the controls (P < 0.001).

Comparison of HRs among the HBV/HCV, HBV, and HCV groups for the risk of SSNHL

Cox proportional hazards regression analysis revealed an increased risk of SSNHL, with an incidence rate ratio (IRR) of 5.743 (95% CI, 4.585–5.678) in the HBV/HCV group, after adjustment for sex, age, and comorbidities. In addition, the individual IRRs for SSNHL in the subgroups of HBV (3.24) and HCV (2.503) were identified. All adjusted HRs for the risk of SSNHL were similar among the HBV/HCV (5.103; 95% CI, 4.585–5.678), HBV (5.110; 95% CI, 4.495–5.809), and HCV (5.094; 95% CI, 4.437–5.848) groups compared with the control group (P < 0.001; Table 3).

Discussion

To the best of our knowledge, this is the first large-scale retrospective matched-cohort study to explore the association between SSNHL and HBV/HCV infection. The main finding of this study was that patients who were diagnosed as having HBV/HCV infections between January 1, 2000, and December 31, 2010, had a significantly higher incidence of SSNHL, with an IRR of 5.743 (P < 0.001), than did the general population without HBV/HCV infections.
Table 1. Characteristics of the study participants at the end of follow-up.

| Variables | Total | With | Without | P |
|-----------|-------|------|---------|---|
| HBV / HCV |       |      |         |   |
| HBV       | 683,768 | 170,942 | 512,826 | 0.001 |
| HCV       | 689,143 | 170,295 | 518,848 | 0.999 |
| Total     | 1,372,911 | 341,237 | 1,031,674 | 0.036 |
| SSNHL     |       |      |         |   |
| Without   | 689,143 | 170,295 | 518,848 | 0.001 |
| With      | 1,625   | 647   | 978     | 0.001 |
| Gender    |       |      |         |   |
| Male      | 440,600 | 110,150 | 330,450 | 0.036 |
| Female    | 243,168 | 60,792 | 182,376 | 0.036 |
| Age group (years) |       |      |         |   |
| 20–29     | 37,142  | 10,218 | 25,124  | 0.036 |
| 30–39     | 76,708  | 20,367 | 56,341  | 0.036 |
| 40–49     | 112,488 | 30,710 | 81,778  | 0.036 |
| 50–59     | 137,940 | 37,765 | 100,175 | 0.036 |
| 60–69     | 132,244 | 33,033 | 99,211  | 0.036 |
| ≥ 70      | 189,046 | 38,849 | 150,197 | 0.036 |
| Diabetes mellitus (DM) |       |      |         |   |
| Without   | 579,370 | 145,758 | 433,612 | 0.001 |
| With      | 104,398 | 36,394 | 68,004  | 0.001 |
| Hypertension |       |      |         |   |
| Without   | 568,594 | 144,676 | 423,918 | 0.001 |
| With      | 115,174 | 40,072 | 75,102  | 0.001 |
| Depression |       |      |         |   |
| Without   | 677,732 | 169,073 | 508,659 | 0.001 |
| With      | 6,036   | 1,869  | 4,167   | 0.001 |
| Stroke    |       |      |         |   |
| Without   | 635,547 | 164,379 | 471,168 | 0.001 |
| With      | 47,861  | 13,261 | 34,600  | 0.001 |
| Chronic Kidney Disease (CKD) |       |      |         |   |
| Without   | 663,782 | 166,862 | 496,920 | 0.001 |
| With      | 19,986  | 5,520  | 14,466  | 0.001 |
| Osteoporosis |       |      |         |   |
| Without   | 683,543 | 170,492 | 513,051 | 0.001 |
| With      | 2,925   | 857    | 2,068   | 0.001 |
| Nephritis, nephrotic syndrome, and nephrosis |       |      |         |   |
| Without   | 638,130 | 160,600 | 477,530 | 0.001 |
| With      | 45,638  | 10,342 | 35,296  | 0.001 |
| Hyperlipidaemia |       |      |         |   |
| Without   | 666,821 | 167,716 | 499,105 | 0.001 |
| With      | 16,947  | 3,226  | 13,721  | 0.001 |
| Systemic lupus erythematosus (SLE) |       |      |         |   |
| Without   | 682,811 | 170,632 | 512,179 | 0.001 |
| With      | 957     | 247    | 710     | 0.001 |

P-value (categorical variable: chi-square/Fisher exact test). DM: ICD-9-CM code, 250; Hypertension: ICD-9-CM codes, 401–405; Depression: ICD-9-CM codes, 296.2–296.3, 296.82, 300.4, and 311; Stroke: ICD-9-CM codes, 430–438; CKD: ICD-9-CM code, 585; Osteoporosis: ICD-9-CM code, 733.0x; Nephritis, nephrotic syndrome, and nephrosis: ICD-9-CM codes, 580–589; Hyperlipidaemia: ICD-9-CM code, 272; SLE: ICD-9-CM code, 710.0. HBV, hepatitis B virus; HCV, hepatitis C virus.

https://doi.org/10.1371/journal.pone.0175266.t001
The prevalence of HBV/HCV infections varies from <0.5% in Western countries to 8%–25% in endemic countries in East Asia [19]. In our study, the prevalence of HBV/HCV infections was 17.4%. Compared with females, males were predominantly infected with HBV/HCV (110,150 males vs. 60,792 females). The age at diagnosis of HBV/HCV infection was usually > 40 years, which was compatible with a previous report describing a mean age at diagnosis of 42 years; 60% of these were male patients [20]. In addition, our study demonstrated that the development of SSNHL was most common in patients aged ≥40 years, and that most patients with development of SSNHL were men (395 males vs. 252 females).

At the end of follow-up, all comorbidities were significantly differentially distributed between the HBV/HCV and control groups (Table 1). In the HVB/HCV group, a lower rate of the participants with individual comorbidity was observed for most comorbidities, whereas for depression and SLE, a higher rate of the participants was observed compared with the control group. A higher frequency of some degree of depression was reported in both hepatitis B and C patients [21]. However, our finding of a higher percentage of SLE in patients with HBV/HCV infection was inconsistent with previous results [22]. Additional in-depth investigations are warranted to explore the codependence among these comorbidities and HBV/HCV infections through multivariate analyses.

Our data revealed that the incidence of SSNHL was approximately two-fold higher in the HBV/HCV group than in the control group, and that this difference was significant. The general estimated incidence of SSNHL varies from 5 to 20 cases per 100,000 per year [1]. In our study, the annual incidence of SSNHL was approximately 38 cases per 100,000 in the HBV/HCV group compared with 19 cases per 100,000 in the control group. The incidence noted in our study was relatively high because the use of a nationwide and large-scale survey may have increased the number of patients treated for SSNHL in outpatient and inpatient departments.

Fig 2. Kaplan–Meier curves for the cumulative risk of SSNHL among patients aged ≥20 years with HBV/HCV infection (stratified by HBV or HCV alone, using the log-rank test).
Table 2. Factors for sudden sensorineural hearing loss at the end of follow-up, stratified by variables assessed through Cox regression analysis.

| Variables                          | With | Without | Ratio | Adjusted HR | 95% CI | 95%CI | P     |
|------------------------------------|------|---------|-------|-------------|--------|-------|-------|
| HBV / HCV With                     | Event PYs | Rate (per 10^5 PYs) | Event PYs | Rate (per 10^5 PYs) |         |       |       |
| Total                              | 647 228,486.24 | 283.17 | 978 1,983,509.96 | 49.31 | 5.743 | 5.103 | 4.585 | 5.678 | <0.001 |
| Gender                             |      |         |       |             |        |       |       |
| Male                               | 395 144,922.93 | 272.56 | 640 1,265,881.36 | 50.57 | 5.390 | 4.825 | 4.216 | 5.521 | <0.001 |
| Female                             | 252 83,563.30 | 301.57 | 338 717,928.60 | 47.08 | 6.405 | 5.582 | 4.686 | 6.651 | <0.001 |
| Age group (years)                  |      |         |       |             |        |       |       |
| 20–29                              | 33 6,456.16 | 511.14 | 14 28,548.24 | 49.04 | 10.423 | 8.967 | 4.716 | 17.050 | <0.001 |
| 30–39                              | 71 20,412.07 | 347.83 | 53 371,528.37 | 79.13 | 4.521 | 4.328 | 3.542 | 5.288 | <0.001 |
| 40–49                              | 111 34,115.41 | 325.37 | 160 223,115.13 | 71.71 | 4.537 | 4.581 | 3.537 | 5.933 | <0.001 |
| 50–59                              | 176 49,194.50 | 357.76 | 294 371,528.37 | 79.13 | 4.521 | 4.328 | 3.542 | 5.288 | <0.001 |
| ≥70                                | 131 68,296.00 | 191.81 | 201 769,637.60 | 55.28 | 7.345 | 6.426 | 5.070 | 8.145 | <0.001 |
| Diabetes mellitus (DM)             |      |         |       |             |        |       |       |
| Without                            | 529 183,848.75 | 287.74 | 740 1,556,145.80 | 47.55 | 6.051 | 5.421 | 4.809 | 6.111 | <0.001 |
| With                               | 118 44,637.48 | 264.35 | 238 427,364.15 | 55.69 | 4.747 | 3.958 | 3.117 | 5.026 | <0.001 |
| Hypertension                       |      |         |       |             |        |       |       |
| Without                            | 533 187,115.65 | 284.85 | 745 1,466,869.58 | 50.79 | 5.609 | 5.016 | 4.456 | 5.646 | <0.001 |
| With                               | 114 41,371.48 | 275.55 | 233 516,404.38 | 45.10 | 6.110 | 5.446 | 4.253 | 6.976 | <0.001 |
| Depression                         |      |         |       |             |        |       |       |
| Without                            | 639 225,164.07 | 283.79 | 974 1,960,769.42 | 49.67 | 5.713 | 5.065 | 4.550 | 5.638 | <0.001 |
| With                               | 8 3,322.17 240.81 | 4 22,740.53 | 17.59 | 13.690 | 15.114 | 4.027 | 56.720 | <0.001 |
| Stroke                             |      |         |       |             |        |       |       |
| Without                            | 628 217,345.56 | 288.94 | 935 1,793,066.24 | 52.15 | 5.541 | 5.019 | 4.503 | 5.594 | <0.001 |
| With                               | 19 11,140.67 170.55 | 43 190,437.2 | 22.58 | 7.553 | 7.721 | 4.317 | 13.608 | <0.001 |
| Chronic Kidney Disease (CKD)       |      |         |       |             |        |       |       |
| Without                            | 634 220,596.40 | 287.40 | 945 1,917,281.65 | 49.29 | 5.831 | 5.208 | 4.673 | 5.804 | <0.001 |
| With                               | 13 7,889.64 164.77 | 33 66,228.30 | 49.83 | 3.307 | 2.356 | 1.188 | 4.672 | 0.014 |
| Osteoporosis                       |      |         |       |             |        |       |       |
| Without                            | 645 227,630.31 | 283.35 | 974 1,970,764.78 | 49.42 | 5.733 | 5.094 | 4.578 | 5.669 | <0.001 |
| With                               | 2 855.92 233.67 | 4 12,745.17 | 31.38 | 7.445 | 8.052 | 1.333 | 48.659 | 0.023 |
| Nephritis, nephrotic syndrome, and nephrosis |     |       |       |             |        |       |       |
| Without                            | 609 210,808.81 | 288.89 | 929 1,839,943.17 | 50.49 | 5.722 | 5.144 | 4.608 | 5.742 | <0.001 |
| With                               | 38 17,677.42 214.96 | 49 143,566.78 | 34.13 | 6.298 | 4.540 | 2.873 | 7.174 | <0.001 |
| Hyperlipidaemia                    |      |         |       |             |        |       |       |
| Without                            | 609 224,485.09 | 271.29 | 929 1,905,167.63 | 48.76 | 5.563 | 4.944 | 4.436 | 5.510 | <0.001 |
| With                               | 38 4,001.15 949.73 | 49 78,342.32 | 62.55 | 15.184 | 12.440 | 6.860 | 22.558 | <0.001 |
| Systemic lupus erythematosus (SLE) |      |         |       |             |        |       |       |
| Without                            | 644 227,931.26 | 282.54 | 975 1,980,062.17 | 49.24 | 5.738 | 5.109 | 4.591 | 5.666 | <0.001 |
| With                               | 3 554.97 540.57 | 3 3,447.79 | 87.01 | 6.213 | 4.032 | 0.701 | 23.198 | 0.118 |

PYs, person-years; adjusted HR, adjusted hazard ratio: adjusted for the variables listed in the Cox regression table; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.
In a previous report, the annual SSNHL incidence in Taiwan ranged between 6.49 and 10.21 per 100,000; this number included only the SSNHL patients with hospital admission [23]. Despite the association between HBV/HCV infection and several risk factors for SSNHL, the risk of SSNHL remained significantly higher in the HBV/HCV infection cohort, after adjustment for sex, age group, and comorbidities. The association between HBV/HCV infections and SSNHL may be because of shared risk factors. However, we can confidently claim that the increased risk of SSNHL in these patients was likely the effect of HBV/HCV infection, because the possible confounding factors for SSNHL were already substantially adjusted for in this study. Even in the subgroups of HBV or HCV infection alone, a significantly increased risk of SSNHL (with a higher adjusted HR) was observed compared with the control group. These data indicate that hepatitis virus infection has a very strong impact on the risk of SSNHL.

The underlying mechanisms linking HBV/HCV infections with SSNHL development remain unclear. We hypothesized that, in patients with HBV/BCV infections, SSNHL could occur due to an acute exacerbation of viral hepatitis and subsequent SNHL [8] or a chronic viral reaction causing chronic hearing loss [24, 25]. Viruses could gain access to the inner ear via the hematogenous route and induce severe pathophysiologic changes or an immune-mediated reaction [8]. HBV/HCV infections can stimulate the production of inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1, and interleukin-6, which are injurious to the cochlear hair cells [26]. In addition, hepatitis virus infection has a well-documented association with polyarteritis nodosa, which is a life-threatening necrotizing vasculitis that may result in hearing loss [24, 27].

Our results demonstrate that a greatly increased risk of SSNHL was observed in patients with HBV/HCV infections, according to the data of a large population (170,942 patients with HBV/HCV and 512,826 controls) selected from a retrospective matched-cohort comprising 1,000,000 people covered by the National Health Insurance program; the large sample size benefitted the statistical analysis. This large data resource enables us to investigate the risk factors for SSNHL in Taiwan, with an acceptable selection bias and an enhanced statistical precision.

Our research has several shortcomings. First, several potentially confounding risk factors, such as alcohol consumption, smoking, ototoxic drug effects, and noise exposure for SSNHL, were unavailable in the data resource, which may have led to a certain bias [28]. Second, the database did not provide audiometric results regarding the degree of hearing impairment or routine blood and biochemistry tests data. Third, a population-based study cannot clarify the real mechanism underlying the association between HBV/HCV infection and SSNHL because extracting cochlear tissue pathogens or detecting cochlear injury through imaging is very difficult [7, 8]. In addition, patients who developed SSNHL due an ototoxic effect after antiviral drug administration for HVB/HCV infection (which has been reported in some studies) could not be excluded [10, 11]. However, a case–control study revealed pegylated interferon plus

| HBV / HCV | With | Without | Ratio | Adjusted HR | 95%CI | 95%CI | P |
|-----------|------|---------|------|-------------|------|------|---|
| Subgroup  | Event PYs Rate (per 10⁵ PYs) | Event PYs Rate (per 10⁵ PYs) |      |             |      |      |   |
| Total     | 647 228,486.24 283.17 | 978 1,983,509.96 49.31 | 5.743 | 5.103 | 4.585 | 5.678 | <0.001 |
| HBV       | 365 228,486.24 159.75 | 978 1,983,509.96 49.31 | 3.240 | 5.110 | 4.495 | 5.809 | <0.001 |
| HCV       | 282 228,486.24 123.42 | 978 1,983,509.96 49.31 | 2.503 | 5.094 | 4.437 | 5.848 | <0.001 |

PYs, person-years; adjusted HR, adjusted hazard ratio: adjusted for the variables listed in the Cox regression table; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.

https://doi.org/10.1371/journal.pone.0175266.t003
ribavirin therapy does not have any impact on the hearing thresholds of patients with HCV [29]. Finally, we could not exclude the possibility of virus-unrelated hepatitis, such as alcohol-related hepatitis, being correlated with the risk of SSNHL. Additional large-scale studies need to be performed to clarify the discrepancy between virus-induced SSNHL and hepatitis-induced SSNHL. Despite these limitations, this study contributes to the awareness of the increased risk of SSNHL in HBV/HCV-infected populations.

Conclusions

In this study, HBV/HCV infections present a clearly elevated risk for SSNHL. Regular audiometric tests are recommended for patients with HBV/HCV infection to assess their hearing ability and enable the earlier detection of SSNHL. We also suggest that HBV or HCV carriers presenting with the sudden onset of hearing loss should be examined for the possibility of acute exacerbation of chronic HBV/HCV infection.

Acknowledgments

This work was supported in part by grants from the Ministry of Science and Technology, Taiwan (MOST 103-2314-B-016-018 -MY2 to HC Chen); Tri-Service General Hospital (TSGH-C105-108 to HC Chen); and National Defense Medical Research grants, Taiwan, ROC (MAB-104-058 and MAB-105-019 to HC Chen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Conceptualization: HCC.

Data curation: CHC WCC.

Formal analysis: CHC WCC.

Funding acquisition: HCC.

Investigation: CHC.

Methodology: WCC.

Project administration: FHL CHT YFW.

Resources: WCC.

Software: CHC.

Supervision: CHW.

Validation: JCL WKC WCC.

Visualization: HCC.

Writing – original draft: HCC WCC.

Writing – review & editing: HCC CHW WCC.

References

1. Byl FM Jr. Sudden hearing loss: eight years' experience and suggested prognostic table. Laryngoscope. 1984; 94(Pt 1):647–61.
2. Masuda M, Kanzaki S, Minami S, Kikuchi J, Kanzaki J, Sato H, et al. Correlations of inflammatory biomarkers with the onset and prognosis of idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2012; 33(7):1142–50. https://doi.org/10.1097/MAO.0b013e3182635417 PMID: 22872174

3. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012; 146(3 Suppl):S1–35.

4. Koide J, Yanagita N, Hondo R, Kurata T. Serological and clinical study of herpes simplex virus infection in patients with sudden deafness. Acta Otolaryngol Suppl. 1988; 456:21–6. PMID: 2852430

5. Cohen BE, Durstenfeld A, Roehm PC. Viral causes of hearing loss: a review for hearing health professionals. Trends Hear. 2014; 18. PubMed Central PMCID: PMC4222184.

6. Mentel R, Kafth H, Wegner U, Reissmann A, Gurtler L. Are enterovirus infections a co-factor in sudden hearing loss? J Med Virol. 2004; 72(4):625–9. https://doi.org/10.1002/jmv.20014 PMID: 14981765

7. Lin C, Lin SW, Weng SF, Lin YS. Increased risk of sudden sensorineural hearing loss in patients with human immunodeficiency virus aged 18 to 35 years: a population-based cohort study. JAMA Otolaryngol Head Neck Surg. 2013; 139(3):251–5. https://doi.org/10.1001/jamaoto.2013.1709 PMID: 23429981

8. Huang CC, Lin WB, Chang PH, Chan KC, Lee TJ. Sudden deafness as a presenting symptom of chronic hepatitis B with acute exacerbation. Otolaryngol Head Neck Surg. 2009; 141(5):659–60. https://doi.org/10.1016/j.otohns.2009.05.006 PMID: 19861211

9. Orlando MP, Masieri S, Pascarella MA, Ciofalo A, Filiaci F. Sudden hearing loss in childhood consequent to hepatitis B vaccination: a case report. Ann N Y Acad Sci. 1997; 830:319–21. PMID: 9616691

10. Mendes-Correia MC, Bittar RS, Salminto N, Oiticica J. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil. Braz J Infect Dis. 2011; 15(1):87–9. PMID: 21412597

11. Gozdas HT, Karabay O. Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment. Indian J Pharmacol. 2015; 47(1):121–2. PubMed Central PMCID: PMC4375807. https://doi.org/10.4103/0253-7613.150377 PMID: 25821325

12. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014; 147(1):143–51 e5. https://doi.org/10.1053/j.gastro.2013.04.048 PMID: 24704525

13. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558–67. https://doi.org/10.1016/S1473-3099(05)70216-4 PMID: 16122679

14. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000; 15 Suppl:E3–6.

15. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987; 257(19):2597–603. PMID: 3573257

16. Chen CH, Yang PM, Huang GT,Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007; 106(2):148–55. https://doi.org/10.1016/S0929-6646(09)60231-X PMID: 17339159

17. Yang JF, Lin CI, Huang JF, Dai CY, Lin WY, Ho CK, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010; 26(9):461–9. https://doi.org/10.1016/S0950-0622(10)60156-X PMID: 20837342

18. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365(12):1118–27. https://doi.org/10.1056/NEJMra1001683 PMID: 21992124

19. Chang MC, Chen CH, Liang JD, Tien YW, Hsu C, Wong JM, et al. Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma. World J Gastroenterol. 2014; 20(17):5060–5. PubMed Central PMCID: PMC4009541. https://doi.org/10.3748/wjg.v20.i17.5060 PMID: 24803819

20. Chen CH, Lin CL, Kao CH. Association between Chronic Hepatitis B Virus Infection and Risk of Osteoporosis: A Nationwide Population-Based Study. Medicine. 2015; 94(50):e2276. https://doi.org/10.1097/MD.0000000000002276 PMID: 26683953

21. Qureshi MO, Khokhar N, Shafqat F. Severity of depression in hepatitis B and hepatitis C patients. J Coll Physicians Surg Pak. 2012; 22(10):632–4. https://doi.org/10.2012/JCPSP.632634 PMID: 23058145

22. Abu-Shakra M, El-Sana S, Margalith M, Sikuler E, Neumann L, Buskila D. Hepatitis B and C viruses serology in patients with SLE. Lupus. 1997; 6(6):543–4. https://doi.org/10.1177/096120339700600612 PMID: 9256314

23. Wu CS, Lin HC, Chao PZ. Sudden sensorineural hearing loss: evidence from Taiwan. Audiol Neurootol. 2006; 11(3):151–6. https://doi.org/10.1159/000091198 PMID: 16449805
24. Nasab MS, Fathololoomi MR, Alizamir A. Association between hepatitis B and hearing status. Oman Med J. 2012; 27(5):418–20. PubMed Central PMCID: PMC3472578. https://doi.org/10.5001/omj.2012.103 PMID: 23074556

25. Pacher BM, Costa MR, Nascimento MM, Moura MC, Passos AD. Hepatitis B and C in a Brazilian deaf community. Rev Soc Bras Med Trop. 2015; 48(5):603–6. https://doi.org/10.1590/0037-8682-0058-2015 PMID: 26516972

26. So H, Kim H, Lee JH, Park C, Kim Y, Kim E, et al. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol. 2007; 8(3):338–55. PubMed Central PMCID: PMC2538433. https://doi.org/10.1007/s10162-007-0084-9 PMID: 17516123

27. Joglekar S, Deroee AF, Morita N, Cureoglu S, Schachern PA, Paparella M. Polyarteritis nodosa: a human temporal bone study. Am J Otolaryngol. 2010; 31(4):221–5. https://doi.org/10.1016/j.amjoto.2009.02.006 PMID: 20015749

28. Lin RJ, Krall R, Westerberg BD, Chadha NK, Chau JK. Systematic review and meta-analysis of the risk factors for sudden sensorineural hearing loss in adults. Laryngoscope. 2012; 122(3):624–35. https://doi.org/10.1002/lary.22480 PMID: 22252719

29. Hagr A, Jamjoom D, Sanai FM, Al Hamoudi W, Abdo AA, Al-Arfaj A. Effect of interferon treatment on hearing of patients with chronic hepatitis C. Saudi J Gastroenterol. 2011; 17(2):114–8. PubMed Central PMCID: PMC3099056. https://doi.org/10.4103/1319-3767.77240 PMID: 21372346